

Material Information (3176 MEDIGEN???????)

SEQ_NO 1 Date of announcement 2024/02/07 Time of announcement 15:18:58
Subject Signing of the sales cooperation agreement for the new drug OBP-301 in Japan.
Date of events 2024/02/07 To which item it meets paragraph 53

Statement

- 1.Date of occurrence of the event:2024/02/07
- 2.Company name:Medigen Biotechnology Corp.
- 3.Relationship to the Company (please enter "head office" or "subsidiaries"):head office
- 4.Reciprocal shareholding ratios:N/A
- 5.Cause of occurrence:
Medigen Biotechnology Corp. and the Japanese publicly traded company Oncolys BioPharma (TSE stock code 4588), are jointly developing the oncolytic virus new drug OBP-301 (Telomelysin). Oncolys announced today (February 7, 2024) that it has reached a cooperation agreement with FUJIFILM Toyama Chemical Co., Ltd. (hereinafter referred to as FUJIFILM Toyama Chemical) for the sales of OBP-301 in Japan. In the future, Oncolys will be responsible for applying for marketing approval and supplying OBP-301, while FUJIFILM Toyama Chemical will be responsible for sales and promotion to medical institutions. This agreement is a sales cooperation agreement and does not include upfront payments. However, if marketing approval is obtained in the future and the targeted sales goals are achieved, Oncolys could receive up to 1.7 billion yen in milestone payments.
- 6.Countermeasures:none
- 7.Any other matters that need to be specified(the information disclosure also meets the requirements of Article 7, subparagraph 9 of the Securities and Exchange Act Enforcement Rules, which brings forth a significant impact on shareholders rights or the price of the securities on public companies.):
 - (1) New drug development involves lengthy timelines, high costs, and success is not guaranteed. Such factors introduce risks to investments, and investors should exercise caution and careful judgment when considering investments.
 - (2) Medigen shares the research and development costs of OBP-301 with Oncolys BioPharma, and will also share future commercial benefits.
 - (3) Link to the announcement by Oncolys BioPharma in Japan:
<https://ssl4.eir-parts.net/doc/4588/tdnet/2390717/00.pdf>